Mirae Asset Global Investments Co. Ltd. Reduces Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Mirae Asset Global Investments Co. Ltd. trimmed its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 22.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,133 shares of the biotechnology company's stock after selling 3,549 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Axon Enterprise were worth $3,134,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of AXON. Capital International Investors grew its position in shares of Axon Enterprise by 605.2% during the 1st quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company's stock valued at $366,449,000 after acquiring an additional 2,283,343 shares during the period. Sands Capital Management LLC grew its holdings in Axon Enterprise by 101.6% during the second quarter. Sands Capital Management LLC now owns 1,993,126 shares of the biotechnology company's stock valued at $388,899,000 after purchasing an additional 1,004,556 shares during the period. BlackRock Inc. increased its position in Axon Enterprise by 11.7% in the first quarter. BlackRock Inc. now owns 8,329,479 shares of the biotechnology company's stock worth $1,872,883,000 after buying an additional 870,481 shares during the last quarter. Norges Bank bought a new stake in shares of Axon Enterprise in the fourth quarter valued at $102,920,000. Finally, Westfield Capital Management Co. LP lifted its position in shares of Axon Enterprise by 184.3% during the 3rd quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company's stock valued at $138,535,000 after buying an additional 451,350 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Price Performance

Shares of AXON traded down $2.23 during trading hours on Thursday, reaching $297.59. 592,268 shares of the company's stock traded hands, compared to its average volume of 468,272. Axon Enterprise, Inc. has a 12 month low of $175.37 and a 12 month high of $329.87. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42. The stock has a market cap of $22.46 billion, a PE ratio of 130.36 and a beta of 0.93. The firm's 50 day simple moving average is $299.84 and its 200-day simple moving average is $257.02.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.29. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The business had revenue of $432.14 million during the quarter, compared to analyst estimates of $418.97 million. Equities analysts expect that Axon Enterprise, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on AXON shares. StockNews.com lowered Axon Enterprise from a "buy" rating to a "hold" rating in a report on Thursday, March 14th. Morgan Stanley raised their price objective on shares of Axon Enterprise from $250.00 to $285.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 28th. Barclays lifted their price objective on shares of Axon Enterprise from $296.00 to $308.00 and gave the company an "overweight" rating in a research note on Thursday, February 29th. JMP Securities increased their target price on Axon Enterprise from $250.00 to $285.00 and gave the stock a "market outperform" rating in a research report on Tuesday, February 6th. Finally, JPMorgan Chase & Co. lifted their price target on Axon Enterprise from $330.00 to $365.00 and gave the company an "overweight" rating in a research report on Thursday, April 11th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $312.64.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.